Last reviewed · How we verify
NCT05191147: PCAFE
Prevalence of Dietary Supplement Consumption Among Pregnant Womenweeks of Pregnancy: a Cross-sectional Telephone Interview Survey
trial testing Dietary supplement in Preference, Consumer in 80 participants. Status unknown.
10 April 2022
Quick facts
| Lead sponsor | University Hospital, Grenoble |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 80 |
| Start date | 1 January 2022 |
| Primary completion | 10 April 2022 |
| Estimated completion | 10 May 2022 |
| Sites | 1 location across France |
Drugs / interventions tested
- Dietary supplement — full drug profile →
Conditions studied
- Preference, Consumer — all drugs for Preference, Consumer →
Sponsor
University Hospital, Grenoble
Who can join
Adults 18 to 45, female only, with Preference, Consumer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Primary endpoint : Prevalence estimation of the dietary supplement consumption among pregnant women during the first 20-25 weeks of pregnancy. Hypothesis of the study : The sale and consumption of dietary supplements in the general population has increased in recent years. It would be interesting to know if this is also the case for pregnant women or if they are more vigilant about their health during this period. It would also allow to identify factors associated with their consumption if it exists. The investigators hypothesize that some women may sometimes fail to mention this supplement intake to care givers and they would like to know if these omissions are voluntary or not.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05191147
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Dietary supplement
Trials testing the same drug.
- NCT05357157 — Electroacupuncture Pain Treatment, Mechanical Hyperalgesia, Quality of Life & Expression of Mu+ B Cells in Fibromyalgia · recruiting
- NCT05199545 — Efficacy Study in Phytotherapy of an Association of Plants in the Improvement of Psychological Well-being · NA · completed
- NCT05323084 — Effect of a Dietary Supplement on Quality of Life · NA · completed
- NCT06031766 — Comparison of CIPA With the GLIM Criteria and Prevalence of Sarcopenia in Inpatients · unknown
- NCT04983017 — 2021 PMT iAge® Intervention Trial by Edifice Health · NA · terminated
Other University Hospital, Grenoble trials
Trials by the same sponsor.
- NCT07479225 — Circulating Cell-Free DNA for Brain Abscess Diagnosis: A Pilot Study · NA · not yet recruiting
- NCT07477613 — Implantable Brain-Computer Interface for Upper-Limb Recovery After Stroke · NA · not yet recruiting
- NCT07379372 — Bladder Overactivity and Post-Botulinum Toxin Telemonitoring · NA · not yet recruiting
- NCT07166991 — Anesthesia sTrategy foR Organ Procurement In braiN dEath · Phase 3 · recruiting
- NCT07367880 — The Monument Test : A New Tool for Assessing the Ability to Name and Identify Unique Entities. (TeDIMO) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05191147 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Grenoble
- Last refreshed: 17 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05191147.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing